BridgeBio Pharma Inc. Publishes Data on Acoramidis’ Effect on Cardiovascular Mortality and Hospitalization in ATTR-CM
Reuters
Sep 28
<a href="https://laohu8.com/S/BBIO">BridgeBio Pharma</a> Inc. Publishes Data on Acoramidis' Effect on Cardiovascular Mortality and Hospitalization in ATTR-CM
BridgeBio Pharma Inc. has published a document detailing the effects of acoramidis (AG10) on cardiovascular mortality and hospitalization in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The document includes results from a randomized controlled trial and open-label extension, focusing on recurrent cardiovascular events and related outcomes. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on September 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.